The lower numbers reported by Genzyme are due to lowered sales of Cerezyme. IOW, it's what I've been saying all along.....that Genzyme is running into headwinds with increasing competition in the rare disease market they once had sole claim to.
This is why Viehbacher was and is a dolt to offer anywhere close to his initial price for Genzyme. Genzyme will be nothing but an anchor on the stock price. Meanwhile, Viehbacher can shuffle papers for a few years "integrating" it all and five years from now, when it's apparent to even the most amateur of analysts it all went nowhere, Viehbacher can exit with his golden parachute.
Viehbacher has as much foresight as a tunneling mole in my backyard.